CD133 + Vesicles Mediate Resistance to RAS-ERK Inhibition Regulated by YAP Activation in Liver Cancer Cells

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

CD133, a pentaspan plasma membrane protein, has been viewed as a biomarker of stem cells in normal and cancer tissues, although its function and mechanism are unclear. In previous studies, we identified a new type of CD133+ intracellular vesicles, named intercellsome, which is implicated in direct cell-cell communication under stress conditions. However, the regulatory mechanism and biological significance of these CD133+ vesicles are largely unknown, highlighting a gap in understanding of this cellular communication mechanism. We show here that CD133 acts as a stress response marker in cancer cells, with its expression and vesicle formation significantly induced under MEK inhibitor-mediated proliferative stress. The CD133+ vesicles are essential for maintaining cell proliferation under stress conditions in vitro. Mechanistically, the MEKi activates the Hippo-YAP signaling pathway, which promotes CD133 transcription, establishing a novel connection between YAP signaling and CD133+ vesicle biogenesis. Further, CD133 plays a critical role in YAP-driven liver cancer progression in mice. This study defines a critical role of CD133+ vesicles in stress response regulated by YAP, which advances the understanding of CD133 functions beyond its stem cell-associated roles and suggests new avenues for therapeutic intervention of liver cancer relapse.

Article activity feed